Nello Mainolfi, Chief Executive Officer at Kymera Therapeutics, Inc. (KYMR), sold 50,000 shares at $119.00 ($6.0M) on 2026-07-07, disclosed to the SEC on 2026-07-07.
Scheduled sale ($6.0M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KYMR | SELL | 2026-04-29 | $2.4M | — | Filing → |
| KYMR | SELL | 2026-02-25 | $2.7M | — | Filing → |
| KYMR | SELL | 2025-12-31 | $4.7M | — | Filing → |